Phospho-CCNB1 (Ser147) Antibody

How does Phospho-CCNB1 (Ser147) function in normal vs. pathological cell cycle regulation?

In normal cell cycle regulation, Phospho-CCNB1 (Ser147) demonstrates a specific temporal pattern of expression and activity. Cyclin B1 undergoes controlled accumulation during G2 phase without ubiquitination, followed by APC-dependent destruction at the end of mitosis. This coordinated phosphorylation and degradation sequence is essential for proper cell cycle progression. The protein exists in two alternative transcript forms: a constitutively expressed transcript and a cell cycle-regulated transcript that predominates during the G2/M phase .

In pathological conditions, particularly cancer, this regulated phosphorylation becomes disrupted. Overexpression of Cyclin B1 has been documented in various malignancies, including breast, prostate, and non-small cell lung cancers. The altered phosphorylation status can lead to abnormal Cyclin B1-CDK1 complex formation and activity, contributing to dysregulated cell division and proliferation characteristic of cancer cells . Researchers should consider these differential patterns when designing experiments to investigate potential therapeutic interventions targeting this pathway.

What experimental approaches can reliably detect Phospho-CCNB1 (Ser147) in research samples?

Several validated experimental approaches can detect Phospho-CCNB1 (Ser147) in research samples with high specificity and sensitivity:

• Western Blotting: Optimal for quantitative assessment of phosphorylation levels, typically using 1:500-1:2000 dilution of primary antibody. This technique allows researchers to evaluate both total and phosphorylated Cyclin B1 levels when appropriate controls are included .

• Immunohistochemistry (Paraffin): Enables visualization of phosphorylated protein in tissue context, particularly valuable for analyzing spatial distribution in tumor samples. Recommended dilution ranges from 1:100-1:300 .

• Immunofluorescence: Provides subcellular localization information, especially useful for tracking phosphorylation changes during different cell cycle phases .

• ELISA-based detection: Particularly valuable for high-throughput screening applications. Colorimetric Cell-Based ELISA kits offer a convenient, lysate-free approach with sensitivity adequate for detecting endogenous levels of phosphorylated protein .

• Chromatin Immunoprecipitation (ChIP): While less common for phosphorylated proteins, this can be used to investigate binding interactions with DNA when combined with regulatory factors .

Researchers should select the appropriate method based on their specific experimental questions, required sensitivity, and available sample types.

What are the optimal sample preparation protocols for different applications of Phospho-CCNB1 (Ser147) antibody?

Sample preparation varies significantly depending on the application, and optimization is critical for reliable Phospho-CCNB1 (Ser147) detection:

For Western Blot Analysis:

• Cell lysis should be performed using buffers containing phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate) to preserve phosphorylation status.

• Quick processing on ice is essential as phosphorylation can be rapidly lost upon cell disruption.

• Samples should be denatured at 95°C for 5 minutes in loading buffer containing SDS and DTT.

• For optimal results, load 20-40 μg of total protein per lane on 10-12% SDS-PAGE gels .

For Immunohistochemistry:

• Tissue fixation in 10% neutral buffered formalin for 24-48 hours is recommended.

• Paraffin embedding should follow standard protocols with careful temperature control.

• Antigen retrieval is critical - heat-induced epitope retrieval using citrate buffer (pH 6.0) typically yields optimal results.

• Endogenous peroxidase blocking with 3% hydrogen peroxide is necessary before antibody incubation .

For Cell-Based ELISA:

• Cells should be cultured in clear bottom 96-well plates at >5000 cells per well.

• Fixation with 4% paraformaldehyde for 20 minutes at room temperature preserves protein conformation.

• Gentle permeabilization with 0.1% Triton X-100 in PBS maintains cellular architecture while allowing antibody access .

The composition of storage buffer (e.g., Dulbecco's PBS with 150mM NaCl, 50% glycerol, and 0.02% sodium azide at pH 7.4) helps maintain antibody stability and activity . Proper storage at -20°C and avoiding repeated freeze-thaw cycles are essential for preserving antibody performance across all applications.

How can researchers validate the specificity of Phospho-CCNB1 (Ser147) antibody detection?

Validating antibody specificity is crucial for reliable experimental outcomes. Multiple complementary approaches should be employed:

Phospho-peptide competition assay:

• Perform parallel experiments with and without pre-incubation of the antibody with the specific phosphopeptide (A-F-SP-D-V, derived from the region surrounding Ser147).

• A significant reduction in signal after phosphopeptide blocking confirms phospho-specificity, as demonstrated in Western blot analysis of Jurkat cells treated with UV and immunohistochemistry of human placenta samples .

Phosphatase treatment controls:

• Treat duplicate samples with lambda phosphatase before immunoblotting.

• The disappearance of signal after phosphatase treatment confirms phospho-specificity.

Stimulation/inhibition experiments:

• Treat cells with known modulators of the pathway (e.g., UV irradiation has been shown to affect Cyclin B1 phosphorylation).

• The expected changes in phosphorylation status following treatment validate both antibody specificity and biological relevance .

Knockdown/knockout validation:

• Perform siRNA knockdown or CRISPR-based knockout of CCNB1.

• The absence of signal in these samples confirms antibody specificity to the target protein.

Cross-reactivity assessment:
The antibody shows validated reactivity with human and mouse samples, with predicted reactivity in other species based on sequence homology . Researchers should perform preliminary validation when working with species not explicitly confirmed in the product documentation.

What are the recommended quantification and normalization approaches for Phospho-CCNB1 (Ser147) experimental data?

Accurate quantification and appropriate normalization are essential for generating reliable and reproducible data:

For Western Blot quantification:

• Densitometric analysis should be performed using specialized software (ImageJ, Image Lab, etc.).

• Multiple normalization strategies are recommended:

  • Normalization to total CCNB1 (ratio of phosphorylated to total protein) provides insight into the proportion of phosphorylated protein.

  • Normalization to housekeeping proteins (β-actin, GAPDH) accounts for loading variations but may not reflect changes in total CCNB1 levels.

• Technical triplicates and biological replicates (n≥3) are essential for statistical validity .

For Cell-Based ELISA:

• The dual detection approach allows measurement of both phosphorylated and total protein in the same well.

• Calculate the ratio of phosphorylated to total protein signal for each well.

• Normalization to cell number using DNA-binding dyes provides an additional layer of standardization .

For Immunohistochemistry/Immunofluorescence:

• Semi-quantitative scoring systems based on staining intensity and percentage of positive cells.

• Digital image analysis using specialized software provides more objective quantification.

• Inclusion of known positive and negative control tissues in each experiment is essential for standardization.

Statistical analysis:
For comparing differences between experimental groups, statistical approaches should include:

• Kruskal-Wallis test or one-way ANOVA followed by Dunnett's post hoc comparison test for multiple groups

• Student's t-test or χ² test for two-group comparisons

• Differences are typically considered significant at p<0.05

This methodical approach to quantification and normalization ensures that the data accurately reflects biological changes in Phospho-CCNB1 (Ser147) levels rather than technical variability.

How can Fluorescence Cross-Correlation Spectroscopy (FCCS) be used to study Phospho-CCNB1 (Ser147) interactions with CDK1?

Fluorescence Cross-Correlation Spectroscopy (FCCS) represents a sophisticated approach for analyzing protein-protein interactions in living cells, including the dynamic binding between Phospho-CCNB1 and CDK1:

Experimental setup:

• Generate cell lines expressing fluorescently tagged proteins:

  • CCNB1-mEmerald (green fluorescent protein)

  • CDK1-mScarlet (red fluorescent protein)

• The temporal correlation between fluorescence fluctuations indicates physical interaction between the proteins, with cross-correlation values (q) of approximately 25-35% observed for the Cyclin B1-CDK1 complex .

Key advantages for phosphorylation studies:

• Enables measurement of dissociation constants (KD) for protein interactions in vivo, which may differ significantly from in vitro measurements.

• Allows temporal tracking of interactions through the cell cycle by synchronizing cells (e.g., using palbociclib for G1 arrest) and measuring at different time points after release.

• Provides spatial information about where in the cell these interactions occur, critical for understanding phosphorylation-dependent localization changes .

Methodological considerations:

• Controls should include single-fluorophore constructs to establish baseline cross-correlation.

• Co-immunoprecipitation followed by immunoblotting can validate interactions observed via FCCS.

• Flow cytometry should be performed in parallel to confirm cell cycle synchrony.

• The technique is particularly valuable at low protein expression levels, though measurements become challenging when Cyclin B1 levels are extremely low (as in early G1 phase) .

This advanced technique offers unique insights into how Ser147 phosphorylation affects the formation, stability, and subcellular localization of the Cyclin B1-CDK1 complex in physiologically relevant conditions.

What experimental approaches can elucidate the relationship between histone deacetylase inhibitors and CCNB1 phosphorylation?

Recent research has revealed intriguing connections between histone deacetylase (HDAC) inhibitors and cell cycle regulatory proteins, including CCNB1. Several experimental approaches can be employed to investigate these relationships:

Chromatin Immunoprecipitation (ChIP) assays:

• Design primers targeting promoter regions of CCNB1 and related cell cycle genes.

• Treat cells with HDAC inhibitors at various concentrations and time points.

• Perform ChIP with antibodies against transcription factors known to regulate CCNB1 (such as FOXM1).

• DNA can be isolated using protease K treatment at 45°C for 30 minutes followed by column purification.

• Quantify binding using qPCR with specific primers for the target promoter regions .

Expression correlation studies:

• Analyze the relationship between HDAC inhibitor-induced changes in CDKN2B/CDKN2D expression and subsequent effects on CCNB1 phosphorylation.

• Western blotting with Phospho-CCNB1 (Ser147) antibody following HDAC inhibitor treatment can reveal temporal relationships between these events.

Cell cycle synchronization experiments:

• Synchronize cells at different cell cycle phases using chemical inhibitors (e.g., palbociclib for G1 arrest).

• Treat with HDAC inhibitors and monitor changes in Phospho-CCNB1 (Ser147) levels over time after release from synchronization.

• This approach allows determination of cell cycle phase-specific effects of HDAC inhibition on CCNB1 phosphorylation .

These methodologies provide complementary insights into how epigenetic regulators, particularly HDAC inhibitors, may influence cell cycle progression through modulation of CCNB1 phosphorylation states.

How can Phospho-CCNB1 (Ser147) analysis contribute to cancer research?

Phospho-CCNB1 (Ser147) analysis offers valuable insights into cancer pathogenesis, progression, and potential therapeutic approaches:

Diagnostic and prognostic applications:

• Immunohistochemical analysis of tumor samples using Phospho-CCNB1 (Ser147) antibodies can reveal aberrant phosphorylation patterns.

• These patterns may correlate with clinical outcomes, helping to identify patient subgroups with different prognoses.

• The antibody has demonstrated efficacy in human placenta samples, suggesting applicability to various tissue types .

Investigation of dysregulated cell cycle mechanisms:

• Cyclin B1 is overexpressed in multiple cancer types, including breast, prostate, and non-small cell lung cancer.

• Analysis of phosphorylation at Ser147 can reveal mechanisms of dysregulated CDK1-Cyclin B1 complex formation.

• Comparison between tumor and adjacent normal tissues can identify cancer-specific alterations in phosphorylation patterns .

Therapeutic response monitoring:

• Cell-based ELISA kits allow high-throughput screening of compounds that modulate CCNB1 phosphorylation.

• This approach facilitates identification of potential cancer therapeutics targeting the cell cycle.

• The technique enables measurement of relative amounts of phosphorylated Cyclin B1 in cultured cells as well as screening for the effects of various treatments, inhibitors (siRNA or chemicals), or activators .

Correlation with other cancer biomarkers:

• Western blotting techniques can be used to analyze relationships between Phospho-CCNB1 (Ser147) levels and other cancer-related signaling pathways.

• Using the recommended dilution of 1:1000 for Western blotting applications ensures optimal signal-to-noise ratio for detecting endogenous protein levels in cancer cell lines .

These applications collectively demonstrate how Phospho-CCNB1 (Ser147) analysis can contribute to a more comprehensive understanding of cancer biology and potentially inform therapeutic strategies.

What are common technical challenges in Phospho-CCNB1 (Ser147) detection and their solutions?

Researchers frequently encounter several challenges when working with Phospho-CCNB1 (Ser147) antibodies:

Loss of phosphorylation during sample preparation:

• Problem: Phosphorylated epitopes are highly susceptible to enzymatic degradation.

• Solution: Always include fresh phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate) in all buffers. Process samples quickly and maintain cold temperatures throughout. For Western blotting, transfer to PVDF membranes rather than nitrocellulose for better retention of phospho-epitopes .

Weak or absent signal in Western blotting:

• Problem: Low abundance of phosphorylated protein or antibody sensitivity issues.

• Solution: Increase protein loading (40-60 μg), optimize antibody concentration (try 1:500 instead of 1:1000), extend primary antibody incubation to overnight at 4°C, and use enhanced chemiluminescence detection systems. Consider enriching phosphorylated proteins using phospho-protein purification kits before Western blotting .

High background in immunohistochemistry:

• Problem: Non-specific binding of antibody.

• Solution: Include a more stringent blocking step (5% BSA instead of 1-3%), optimize antibody dilution (start with 1:100-1:300 range), reduce primary antibody incubation time, and include additional washing steps. The phospho-peptide competition control is essential for distinguishing specific from non-specific signals .

Variability between experiments:

• Problem: Inconsistent results between replicates.

• Solution: Standardize all protocols rigorously, including cell culture conditions, as phosphorylation status can be affected by cell density, serum levels, and stress. Include positive controls (e.g., UV-treated Jurkat cells) in each experiment. Implement quantitative normalization using total CCNB1 levels .

Cell type-specific differences:

• Problem: Antibody performance varies between cell lines or tissue types.

• Solution: Validate the antibody in each new cellular system. The antibody has confirmed reactivity with human and mouse samples, but optimization may be required for different cell types. Consider adjusting lysis conditions based on the particular cellular context .

How should researchers interpret data when total CCNB1 and Phospho-CCNB1 (Ser147) measurements appear contradictory?

When faced with seemingly contradictory data between total CCNB1 and its phosphorylated form at Ser147, careful analytical approaches are necessary:

Possible biological explanations:

• Cell cycle-dependent phosphorylation: Phosphorylation at Ser147 occurs during specific cell cycle phases, particularly G2/M transition. Asynchronous cell populations may show variable ratios of phosphorylated to total protein.

• Rapid phosphorylation dynamics: Phosphorylation can be transient, with rapid turnover that may not correlate with total protein levels.

• Spatial regulation: Phosphorylated CCNB1 may be compartmentalized differently than the total protein pool, affecting detection depending on the experimental approach .

Methodological considerations:

• Antibody epitope accessibility: Protein-protein interactions or conformational changes can mask epitopes in either phosphorylated or total protein detection.

• Technical sensitivity differences: Antibodies against phosphorylated and total forms often have different affinities and detection limits.

Resolution strategies:

• Cell synchronization: Synchronize cells at specific cell cycle phases to establish baseline ratios of phosphorylated to total CCNB1.

• Time-course experiments: Perform fine-grained temporal analysis to capture transient phosphorylation events.

• Subcellular fractionation: Analyze cytoplasmic and nuclear fractions separately to account for phosphorylation-dependent localization changes.

• Multiple detection methods: Combine Western blotting with immunofluorescence or ELISA to obtain complementary data .

Analytical approach:
Create a table documenting contradictory measurements with experimental conditions:

This systematic approach helps distinguish biological insights from technical artifacts when interpreting apparently contradictory data.

What are the key considerations for designing tissue microarray studies using Phospho-CCNB1 (Ser147) antibodies?

Tissue microarray (TMA) studies with Phospho-CCNB1 (Ser147) antibodies require careful planning to ensure valid and reproducible results:

Tissue selection and array design:

• Include multiple cores (minimum 2-3) per patient sample to account for tumor heterogeneity.

• Incorporate positive controls (placenta, actively dividing tissues) and negative controls (quiescent tissues) in each TMA block.

• Consider including matched normal adjacent tissue for comparative analysis with tumor samples.

• Organize samples to allow for batch effect assessment (e.g., arrange by tissue type rather than clinical outcome) .

Antibody validation for TMA:

• Perform full-section immunohistochemistry on representative cases before TMA construction to understand staining patterns and heterogeneity.

• Conduct phospho-peptide competition assays on TMA sections to confirm specificity.

• Include UV-treated cell pellets embedded in the TMA as additional positive controls .

Staining protocol optimization:

• Antigen retrieval is critical - test multiple conditions (citrate pH 6.0, EDTA pH 9.0) to determine optimal protocol.

• Dilution testing should range from 1:50 to 1:300 to establish optimal antibody concentration.

• Consider automated staining platforms for consistency across multiple TMA slides.

• Include a phosphatase inhibitor in buffers to prevent epitope loss during processing .

Scoring and analysis:

• Develop a clear scoring system that captures both intensity and percentage of positive cells.

• Implement digital image analysis when possible for more objective quantification.

• Use multiple independent scorers and assess inter-observer variability.

• Correlate phosphorylation status with clinical parameters and other biomarkers.

Statistical considerations:

• Power calculations should determine adequate sample size for detecting significant associations.

• Appropriate statistical tests include χ² test for categorical correlations and survival analysis (e.g., Kaplan-Meier with log-rank test).

• Account for multiple testing when analyzing associations with numerous clinicopathological variables .

This systematic approach to TMA design, optimization, and analysis maximizes the research value while controlling for technical variables that could confound interpretation of Phospho-CCNB1 (Ser147) expression patterns.

What emerging technologies might enhance detection and functional analysis of Phospho-CCNB1 (Ser147)?

Several cutting-edge technologies show promise for advancing our understanding of Phospho-CCNB1 (Ser147) biology:

Mass spectrometry-based phosphoproteomics:

• Enables unbiased, comprehensive detection of multiple phosphorylation sites simultaneously.

• Can reveal previously uncharacterized phosphorylation events that crosstalk with Ser147.

• Quantitative approaches like SILAC (Stable Isotope Labeling with Amino acids in Cell culture) or TMT (Tandem Mass Tag) labeling allow precise measurement of phosphorylation dynamics.

• Integration with proximity labeling techniques (BioID, APEX) can identify phosphorylation-dependent interaction partners.

Live-cell imaging with phospho-specific sensors:

• Building on existing FCCS approaches, genetically encoded biosensors could be developed to monitor Ser147 phosphorylation in real-time.

• FRET (Förster Resonance Energy Transfer)-based reporters can detect conformational changes associated with phosphorylation events.

• These approaches would complement current findings on Cyclin B1-Cdk1 interactions measured by cross-correlation methods (q ∼ 25%–35%) .

CRISPR-based functional genomics:

• Generation of phospho-mimetic (S147D) or phospho-dead (S147A) mutants using CRISPR-Cas9 gene editing.

• Allows direct assessment of the functional consequences of altered phosphorylation status.

• Combinatorial approaches with other phosphorylation sites can decode the "phosphorylation code" regulating Cyclin B1.

Single-cell phospho-proteomics:

• Emerging technologies allow phosphorylation analysis at single-cell resolution.

• Will reveal cell-to-cell heterogeneity in phosphorylation states, particularly relevant in cancer research.

• Can be combined with single-cell transcriptomics for multi-modal analysis of phosphorylation and gene expression.

These technological advances promise to enhance our understanding of the complex regulation of Cyclin B1 through Ser147 phosphorylation and its implications for cell cycle control and disease states.

How might research on Phospho-CCNB1 (Ser147) contribute to targeted cancer therapies?

The strategic targeting of cell cycle regulators represents a promising approach in oncology, with Phospho-CCNB1 (Ser147) offering several potential therapeutic applications:

Biomarker development:

• Phospho-CCNB1 (Ser147) status could serve as a predictive biomarker for response to CDK inhibitors or other cell cycle-targeted therapies.

• Immunohistochemical analysis using validated antibodies against this phosphorylation site could facilitate patient stratification in clinical trials.

• The established reactivity of these antibodies with human samples makes this application clinically feasible .

Target identification:

• Understanding the kinases responsible for Ser147 phosphorylation may reveal new therapeutic targets.

• The signaling pathways regulating this phosphorylation event could be exploited for synthetic lethality approaches in cancer cells with specific genetic backgrounds.

• High-throughput screening using cell-based ELISA methods can identify compounds that modulate this phosphorylation state .

Combination therapy strategies:

• Correlating Phospho-CCNB1 (Ser147) levels with response to standard therapies could inform rational combination strategies.

• HDAC inhibitors have demonstrated effects on cell cycle regulators, suggesting potential synergy with therapies targeting the Cyclin B1-CDK1 axis .

• Understanding the temporal dynamics of phosphorylation through cell cycle phases can help optimize the timing and sequence of combination treatments .

Drug resistance mechanisms:

• Changes in Phospho-CCNB1 (Ser147) levels might contribute to resistance against cell cycle-targeted therapies.

• Monitoring these changes during treatment could provide early indicators of developing resistance.

• Developing strategies to overcome such resistance could improve the durability of treatment responses.

This research direction illustrates how fundamental biochemical understanding of Phospho-CCNB1 (Ser147) regulation can ultimately translate into clinical applications, potentially improving outcomes for cancer patients through more precise and effective therapeutic strategies.